Table 2 Clinicopathological characteristics in patients undergoing potentially curative surgery and adjuvant 5-FU chemotherapy for colorectal cancer (n=222) and survival

From: The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer

 

No adjuvant chemotherapy ( n =172)

 

Adjuvant chemotherapy ( n =50)

 
 

HR (95% CI)

P -value

HR (95% CI)

P -value

Univariate analysis

    

 Age (<65/65–74/⩾75) years

2.33 (1.48–3.68)

<0.001

0.73 (0.31–1.71)

0.464

 Sex (male/female)

1.37 (0.77–2.46)

0.287

1.55 (0.55–4.36)

0.411

 Site (colon/rectum)

1.23 (0.69–2.21)

0.477

1.19 (0.43–3.29)

0.735

 Dukes stage (A/B/C)

1.75 (1.06–2.89)

0.029

3.36 (0.44–25.85)

0.245

 C-reactive protein (⩽10, >10 mg l−1)

2.39 (1.32–4.34)

0.004

6.68 (2.05–21.72)

0.002

 Albumin (⩾35/<35 g l−1)

1.42 (0.59–3.40)

0.433

  

Multivariate analysis

    

 Age (<65/65–74/⩾75) years

1.87 (1.13–3.09)

0.015

1.21 (0.47–3.15)

0.693

 Sex (male/female)

1.08 (0.55–2.09)

0.828

0.92 (0.26–3.22)

0.894

 Site (colon/rectum)

1.57 (0.81–3.07)

0.185

1.15 (0.31–4.27)

0.834

 Dukes stage (A/B/C)

1.39 (0.82–2.36)

0.219

2.56 (0.31–21.21)

0.384

 C-reactive protein (⩽10, >10 mg l−1)

2.10 (1.04–4.25)

0.039

5.57 (1.32–23.51)

0.019

 Albumin (⩾35/<35 g l−1)

1.18 (0.48–2.88)

0.721

  
Back to article page